Citizens Jmp Lowers Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $132.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price objective decreased by stock analysts at Citizens Jmp from $140.00 to $132.00 in a report released on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective suggests a potential upside of 38.99% from the company’s current price.

Several other equities analysts have also issued reports on the company. Wall Street Zen raised Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Royal Bank Of Canada initiated coverage on shares of Mirum Pharmaceuticals in a report on Tuesday, February 17th. They issued an “outperform” rating and a $130.00 price objective for the company. Leerink Partners set a $100.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, December 10th. Finally, Morgan Stanley raised their price target on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $111.75.

Mirum Pharmaceuticals Trading Down 12.6%

Shares of NASDAQ:MIRM traded down $13.65 during mid-day trading on Thursday, reaching $94.97. 253,699 shares of the company were exchanged, compared to its average volume of 738,796. Mirum Pharmaceuticals has a 1 year low of $36.88 and a 1 year high of $109.28. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The firm’s 50-day simple moving average is $92.67 and its 200 day simple moving average is $78.81. The firm has a market cap of $4.88 billion, a price-to-earnings ratio of -110.06 and a beta of 0.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The firm had revenue of $148.93 million during the quarter, compared to analysts’ expectations of $141.78 million. During the same period in the previous year, the firm earned $1.00 EPS. The firm’s revenue for the quarter was up 49.8% compared to the same quarter last year. Equities research analysts forecast that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Insider Activity at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 3,143 shares of Mirum Pharmaceuticals stock in a transaction on Monday, January 26th. The shares were sold at an average price of $96.19, for a total transaction of $302,325.17. Following the completion of the sale, the chief operating officer directly owned 23,286 shares of the company’s stock, valued at approximately $2,239,880.34. The trade was a 11.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Christopher Peetz sold 9,108 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $940,856.40. Following the transaction, the chief executive officer owned 160,294 shares of the company’s stock, valued at approximately $16,558,370.20. The trade was a 5.38% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,136 shares of company stock worth $4,352,029 over the last ninety days. 14.36% of the stock is currently owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC increased its holdings in shares of Mirum Pharmaceuticals by 21.4% in the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock valued at $479,050,000 after acquiring an additional 1,067,722 shares during the last quarter. State Street Corp boosted its holdings in Mirum Pharmaceuticals by 59.2% in the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after purchasing an additional 797,088 shares in the last quarter. Wellington Management Group LLP increased its stake in Mirum Pharmaceuticals by 566.8% in the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after purchasing an additional 672,118 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Mirum Pharmaceuticals by 709.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after purchasing an additional 536,674 shares during the last quarter. Finally, Voloridge Investment Management LLC raised its holdings in Mirum Pharmaceuticals by 2,116.6% during the third quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock worth $28,560,000 after purchasing an additional 371,999 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.